For the quarter ended March 2025, Medical Properties (MPW) reported revenue of $223.8 million, down 17.5% over the same period last year. EPS came in at $0.14, compared to -$1.23 in the year-ago quarter.The reported revenue represents a surprise of -5.10% over the Zacks Consensus Estimate of $235.83 million. With the consensus EPS estimate being $0.15, the EPS surprise was -6.67%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to dete ...

Core Insights - Kellanova reported $3.08 billion in revenue for the quarter ended March 2025, reflecting a year-over-year decline of 3.7% and an EPS of $0.90, down from $1.01 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $3.11 billion by 0.78%, and the EPS was 8.16% below the consensus estimate of $0.98 [1] Financial Performance Metrics - Net sales in the AMEA region decreased by 13.6%, compared to an estimated decline of 11.2% [4] - In Latin America, net sales saw a volume impact decline of 6.2%, against an expected increase of 0.3% [4] - Total reported growth in AMEA was 3.3%, surpassing the estimated decline of 4.7% [4] - Total reported growth in Latin America was -15.2%, worse than the estimated decline of 8.9% [4] - Total reported growth in Europe was -3.4%, compared to an estimated decline of 2.1% [4] - Total reported growth in North America was -4.1%, against an estimated decline of 1.5% [4] - Net sales in North America were $1.62 billion, below the estimated $1.66 billion, representing a year-over-year decline of 4.1% [4] - Net sales in AMEA were $620 million, exceeding the estimated $571.91 million, showing a year-over-year increase of 3.3% [4] - Net sales in Latin America were $266 million, below the estimated $285.85 million, reflecting a year-over-year decline of 15.3% [4] - Net sales in Europe were $579 million, slightly below the estimated $586.27 million, indicating a year-over-year decline of 3.3% [4] Stock Performance - Kellanova shares returned +0.4% over the past month, while the Zacks S&P 500 composite declined by -0.7% [3] - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3]

For the quarter ended March 2025, Becton Dickinson (BDX) reported revenue of $5.27 billion, up 4.5% over the same period last year. EPS came in at $3.35, compared to $3.17 in the year-ago quarter.The reported revenue represents a surprise of -1.74% over the Zacks Consensus Estimate of $5.37 billion. With the consensus EPS estimate being $3.28, the EPS surprise was +2.13%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

Core Insights - Eli Lilly reported a revenue of $12.73 billion for the quarter ended March 2025, marking a 45.2% increase year-over-year, with an EPS of $3.34 compared to $2.58 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $12.62 billion by 0.86%, while the EPS fell short of the consensus estimate of $3.52 by 5.11% [1] Financial Performance - Key metrics indicate that Eli Lilly's shares have returned +9.9% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Sales Breakdown - Verzenio in the U.S. generated net sales of $657.60 million, below the average estimate of $720.57 million, reflecting a year-over-year increase of 3% [4] - Neuroscience products in the U.S. achieved net sales of $189.30 million, slightly above the average estimate of $188.66 million, with a year-over-year growth of 16% [4] - Geographic revenue from the U.S. reached $8.49 billion, slightly below the $8.50 billion estimate, representing a 49.1% year-over-year increase [4] - Humalog's net sales were $335.10 million, below the average estimate of $361.22 million, showing a year-over-year decline of 1% [4] - Cyramza's total net sales were $224.90 million, slightly below the estimate of $227.45 million, with a year-over-year decrease of 2.2% [4] - Humulin's net sales were $173.20 million, significantly below the estimate of $203.01 million, reflecting a 16% year-over-year decline [4] - Forteo's net sales were $66.60 million, exceeding the average estimate of $50.84 million, with an 8.7% year-over-year increase [4] - Erbitux's net sales were $149 million, slightly above the estimate of $146.04 million, indicating a 3% year-over-year increase [4] - Alimta's net sales were $28.20 million, significantly below the estimate of $46.13 million, showing a 59.4% year-over-year decline [4] - Other pharmaceuticals generated net sales of $212.90 million, slightly below the estimate of $213.18 million, reflecting a 12% year-over-year decline [4] - Oncology products achieved net sales of $1.95 billion, below the average estimate of $2.07 billion, with a year-over-year increase of 7.6% [4]

Core Insights - Wesco International reported $5.34 billion in revenue for Q1 2025, a slight year-over-year decline of 0.1% and an EPS of $2.21, down from $2.30 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $5.23 billion by 2.10%, while the EPS fell short of the consensus estimate of $2.23 by 0.90% [1] Financial Performance Metrics - Net Sales for Electrical & Electronic Solutions (EES) were $2.07 billion, matching the four-analyst average estimate, with a year-over-year decline of 1.6% [4] - Net Sales for Utility & Broadband Solutions (UBS) were $1.28 billion, below the four-analyst average estimate of $1.36 billion, reflecting a significant year-over-year decline of 19.2% [4] - Net Sales for Communications & Security Solutions (CSS) reached $2 billion, surpassing the $1.82 billion average estimate, with a year-over-year increase of 19.8% [4] Adjusted EBITDA Analysis - Adjusted EBITDA for Corporate was -$128.70 million, slightly worse than the average estimate of -$126.37 million [4] - Adjusted EBITDA for UBS was $138.30 million, below the four-analyst average estimate of $146.25 million [4] - Adjusted EBITDA for CSS was $158.50 million, exceeding the average estimate of $143.46 million, while EES reported $142.60 million, below the average estimate of $163.59 million [4] Stock Performance - Wesco International's shares returned +0.4% over the past month, contrasting with a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Sotera Health Company (SHC) reported $254.52 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 2.6%. EPS of $0.14 for the same period compares to $0.13 a year ago.The reported revenue represents a surprise of +3.63% over the Zacks Consensus Estimate of $245.61 million. With the consensus EPS estimate being $0.12, the EPS surprise was +16.67%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...

2025年4月29日，天润乳业(600419.SH)发布2025年一季报。 公司营业总收入为6.25亿元，在已披露的同业公司中排名第12，较去年同报告期营业总收入减少1603.94万元，同比较去年同期下降2.50%。归母净利润 为-7330.36万元，在已披露的同业公司中排名第27，较去年同报告期归母净利润减少7784.71万元，同比较去年同期下降1713.36%。经营活动现金净流入为 4753.40万元，在已披露的同业公司中排名第10，较去年同报告期经营活动现金净流入增加5379.85万元。 公司最新资产负债率为55.83%，在已披露的同业公司中排名第19，较上季度资产负债率减少1.44个百分点，较去年同期资产负债率增加2.10个百分点。 公司最新毛利率为14.63%，在已披露的同业公司中排名第24，较上季度毛利率减少2.13个百分点，较去年同期毛利率减少1.81个百分点。最新ROE 为-3.13%，在已披露的同业公司中排名第27，较去年同期ROE减少3.32个百分点。 公司摊薄每股收益为-0.23元，在已披露的同业公司中排名第27，较去年同报告期摊薄每股收益减少0.25元，同比较去年同期下降1713.89 ...

Core Insights - eBay reported revenue of $2.59 billion for the quarter ended March 2025, reflecting a 1.1% increase year-over-year and surpassing the Zacks Consensus Estimate of $2.55 billion by 1.49% [1] - The company's EPS for the quarter was $1.38, up from $1.25 in the same quarter last year, exceeding the consensus EPS estimate of $1.34 by 2.99% [1] Financial Performance Metrics - Gross merchandise volume (GMV) reached $18.75 billion, exceeding the seven-analyst average estimate of $18.54 billion [4] - International GMV was reported at $9.69 billion, slightly above the five-analyst average estimate of $9.68 billion [4] - US GMV was $9.07 billion, surpassing the average estimate of $8.85 billion from five analysts [4] - Active buyers totaled 134 million, closely aligning with the average estimate of 134.14 million based on five analysts [4] Stock Performance - eBay's shares have returned -0.9% over the past month, compared to a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

For the quarter ended March 2025, VICI Properties Inc. (VICI) reported revenue of $984.2 million, up 3.4% over the same period last year. EPS came in at $0.58, compared to $0.57 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $985.56 million, representing a surprise of -0.14%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

Caesars Entertainment, Inc. (CZR) reported mixed first-quarter 2025 results with earnings missing the Zacks Consensus Estimate and revenues surpassing the same. Nonetheless, both top and bottom lines improved on a year-over-year basis.The company’s first-quarter performance was driven by record results in the Digital segment. Growth in the regional segment, supported by recently opened properties, and solid performance in Las Vegas, despite a tough comparison to last year’s Super Bowl period, also aided the ...